Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.YM Bio reports positive data from child cancer trial
Six of the 17 children who were fully evaluable at the time of the conference were reported to have demonstrated either stable disease or a partial response to
Six of the 17 children who were fully evaluable at the time of the conference were reported to have demonstrated either stable disease or a partial response to
Published in the April 1, 2005 issue of CANCER, the new analysis of data from the prostate cancer prevention trial (PCPT) indicates that any possible increase in the
The clinical trial results, including pharmacokinetic data and updated visual acuity outcomes, came from a multi-center open-label US phase II clinical trial with Evizon (squalamine lactate) for the
In 2004, BCY announced the results from a phase II clinical study which led to the agreement with Align. The agreement provides for the continued development of DCF
Intarcia’s objective with the combined anti-estrogen therapy (CAT) study is to test the hypothesis that its combination of atamestane plus toremifene (Orion Pharma’s Fareston) will be more active
The study was designed to determine whether the company’s proprietary substance, Homspera, is effaceable in blocking the development of airway hyperreactivity. The results indicate that Homespera could be
According to a statement from Mylan Laboratories, this decision comes as, following discussions, the two companies were “not able to agree upon terms for a revised transaction”. Mylan
The approval of Pegasys (peginterferon alfa-2a) in combination with Copegus (ribavirin, USP) for the treatment of hepatitis C in HIV patients was based on results from the largest
The phase III study showed that administering Neulasta (pegfilgrastim), beginning in the first and subsequent cycles of chemotherapy, reduced the incidence of febrile neutropenia (low white blood cell
The study of the compound, a partial agonist of the nicotinic alpha-7 receptor, is being conducted in Toronto, Canada, under a clinical trial application that Memory Pharmaceuticals filed